The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Natural history of patients with advanced CCA with FGFR2 gene alterations or wild-type FGFR2
Cholangiocarcinoma (CCA) is a rare and molecularly heterogeneous disease typically associated with a poor prognosis; 10-16% of patients also present with FGFR2 fusions which allow for molecularly targeted therapies. Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses the findings of a retrospective, observational, natural history study using US-based genomic information to compare overall survival in patients with advanced CCA and FGFR2 fusions/rearrangements versus those with wild-type FGFR2. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
